Psilocybin for Trauma
(NWTTPS Trial)
Trial Summary
What is the purpose of this trial?
This trial tests the use of psilocybin microdosing to help patients with chronic illnesses like PTSD and depression. Psilocybin, found in certain mushrooms, helps the brain form new pathways, reducing negative thoughts. This approach targets patients who don't respond well to traditional treatments. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as breakthrough therapy by the FDA.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug psilocybin for treating trauma?
Research suggests that psilocybin, found in 'magic mushrooms', has shown promise in treating mental health issues like major depressive disorder and addiction, which are often related to trauma. While specific data on trauma is limited, the positive effects seen in these related conditions suggest potential benefits for trauma treatment.12345
Is psilocybin generally safe for humans?
Psilocybin has been studied for safety in various conditions, showing that while some people may experience challenging experiences or mild side effects, serious adverse events are rare when used in controlled settings with proper support. In studies, most side effects were mild and resolved quickly, and the risk of enduring psychological distress is low when participants are screened and supported.36789
How does the drug psilocybin differ from other treatments for trauma?
Psilocybin is unique because it is a psychedelic compound that may help treat trauma by promoting neuroplasticity (the brain's ability to change and adapt) and facilitating fear extinction, which are not typical mechanisms of action for standard PTSD treatments. Unlike many current treatments, psilocybin is administered in a few sessions and has shown potential for long-term improvements even in treatment-resistant cases.18101112
Research Team
Ross M Allison, Provider
Principal Investigator
NW Therapies Trauma Unit
Eligibility Criteria
This trial is for individuals with traumatic brain injury or wounds who have chronic conditions like PTSD, depression, MS, HIV, and Long Haulers Syndrome. Participants must consent to the study and be evaluated by a psychiatrist or therapist. Those with cardiovascular complications cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
On-boarding
Participants are onboarded into the study by a team including a Psychiatrist, Therapist, and Micro Dosing Advisor
Treatment
Participants receive enhanced micro-dosing of psilocybin every other day for 5 days, then M/W/F for 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Trauma
Find a Clinic Near You
Who Is Running the Clinical Trial?
NWTraumatherapies
Lead Sponsor
World Health Organization
Collaborator